Breast Cancer Update, Issue 3, 2019 — Part 1: Our interview with
Dr Goetz highlights the following topics as well as cases from his
practice:
Case: A woman in her mid-30s with de novo
ER-positive, HER2-negative metastatic breast cancer (mBC) achieves
a complete clinical response to palbociclib, letrozole and ovarian
suppression (00:00)
Importance of providing support to patients and their families
coping with a diagnosis of mBC (01:15)
Therapeutic options for patients with de novo ER-positive,
HER2-negative mBC (03:45)
Activity and tolerability of gonadotropin-releasing hormone
agonists (05:35)
Selection of patients for treatment with CDK4/6 inhibitors in
combination with endocrine therapy (09:07)
Mechanism of action of CDK4/6 inhibitors (12:13)
Role of everolimus and alpelisib in the management of
ER-positive mBC (14:30)
Implications of ESR1 mutations for the management of
ER-positive mBC; use of selective estrogen receptor degraders
(SERDs) (16:15)
Activity of the selective estrogen receptor modulators
endoxifen and lasofoxifene for mBC with ESR1 mutation (19:48)
Tolerability profiles of the CDK4/6 inhibitors palbociclib,
ribociclib and abemaciclib; dose reduction to mitigate side effects
(21:21)
CNS penetration of abemaciclib; management of
abemaciclib-associated diarrhea (25:26)
Effects of site and extent of metastases on outcomes with
CDK4/6 inhibitors (27:02)
Efficacy of CDK4/6 inhibitors in combination with endocrine
therapy for ER-positive mBC (29:29)
Survival outcomes with CDK4/6 inhibitors and endocrine therapy
for ER-positive mBC (31:28)
Response to palbociclib and endocrine therapy in patients with
ER-positive mBC (34:17)
Selection of therapy for patients with locally advanced
ER-positive, HER2-negative breast cancer (36:41)
Therapeutic approach for patients who experience disease
progression on a CDK4/6 inhibitor (39:33)
Activity of alpelisib for ER-positive advanced breast cancer
with a PIK3CA mutation (47:02)
Side-effect profile of alpelisib (49:41)
Case: A woman in her late 60s with high-grade,
ER-positive, HER2-negative breast cancer and a 21-gene assay
Recurrence Score (RS) of 52 receives adjuvant chemotherapy
(52:54)
Role of bone-modifying agents for patients with ER-positive
breast cancer and bone metastases (58:04)
Ongoing investigations of CDK4/6 inhibitors in the adjuvant
setting (59:40)
Effects of CDK4/6 inhibitors on immunity; potential for
combination with immune checkpoint inhibitors (1:01:14)
TAILORx trial: Adjuvant chemotherapy guided by a 21-gene
expression assay for women with ER-positive, HER2-negative,
node-negative breast cancer (1:06:19)
Impact of clinical risk on prognosis and prediction of
chemotherapy benefit by age and RS in the TAILORx study for
patients with early breast cancer (1:07:46)
Perspective on the use of gene expression assays to determine
risk of recurrence and guide adjuvant decision-making
(1:14:30)
Cancer cell dormancy and risk of late recurrence (1:16:47)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.